Filing Flows › Avita Medical (RCEL) › Q3 2026
Avita Medical (RCEL) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Avita Medical (RCEL) reported revenue of $26.1M for the third quarter 2026 (Q3 2026), +53% from a year earlier and +20% from the quarter before. Operating margin was -10.1%, net loss $6.2M (23.8% of revenue).
Avita Medical, Q3 2026: revenue $26.1M (+53% year over year), operating margin -10.1%, net loss $6.2M, operating cash flow −$710K. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $26.1M | +20% | +53% |
| Operating profit | −$2.6M | — | — |
| Net earnings | −$6.2M | — | — |
| Operating cash flow | −$710K | — | — |
What changed
Revenue was $26.1M in Q3 2026, up 53% year over year and up 20% from the previous quarter.
Gross margin was 84.0%, up 2.7 points from a year earlier. Operating costs exceeded revenue by $2.6M, an operating margin of -10.1%. Operating expenses grew 7% against revenue growth of 53%. The fastest-growing cost line was Research & development (+25%). The quarter ended with a net loss of $6.2M, narrower than the previous quarter's $7.7M loss. Net interest and other expense of $3.5M was the main reason.
Operating cash flow was −$710K. Non-cash charges added back $592K of depreciation and amortization and $1.7M of share-based compensation. Working capital and other items added $3.3M. Capital expenditures of $111K exceeded it, leaving free cash flow of −$821K.
Questions
What was Avita Medical's revenue in the third quarter 2026?
Avita Medical (RCEL) reported revenue of $26.1M for the third quarter 2026 (Q3 2026), +53% from a year earlier and +20% from the quarter before.
Was Avita Medical profitable in the third quarter 2026?
Operating loss was $2.6M (-10.1% of revenue) and net loss $6.2M.
Source: Avita Medical 10-Q on SEC EDGAR.